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Sensorineural hearing loss, which is mainly caused by cochlear hair cell damage, 
is an intractable disease, as cochlear hair cells and supporting cells are unable 
to proliferate in postnatal mammals. As a novel and potent treatment for 
sensorineural hearing loss, we have studied IGF-1 and found that it protects 
cochlear hair cells from the damage caused by noise and ischemic trauma. 
Through a clinical trial, we have also confirmed that IGF-1 is an effective 
treatment for idiopathic sudden sensorineural hearing loss. In the current study, 
we attempted to identify the downstream pathways of the IGF-1 signal and the 
mechanisms by which IGF-1 protects the neonatal mouse cochlear hair cells 
that have been damaged by neomycin. IGF-1 activated both the PI3K/Akt and 
MEK/ERK pathways to maintain the hair cell numbers in the injured cochlea. 
The PI3K/Akt pathway specifically protected the cochlear inner hair cells 
through the inhibition of apoptosis. In contrast, the MEK/ERK pathway 
induced the cell cycle promotion of Hensen’s and Claudius’ cells, the supporting 
cells that are located lateral to the outer hair cells of the cochlea. This cell cycle 
promotion of the supporting cells resulted in the maintenance of the outer hair 
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cell numbers. These results indicate that IGF-1 is a growth factor that 
efficiently regulates different mechanisms through different downstream 
cascades, thereby protecting cochlear hair cells. 
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Introduction 
Insulin-like growth factor 1 (IGF-1) is a polypeptide endocrine hormone that 
functions after birth to facilitate cell growth; IGF-1 also controls cell 
proliferation, differentiation, and apoptosis (Jenkins and Bustin, 2004; 
Varela-Nieto et al., 2007). IGF-1 plays pivotal roles in various organs. For 
example, in the central nervous system, IGF-1 promotes neuronal growth, 
protects neurons and oligodendrocytes from cell death, and stimulates the 
proliferation of neuronal precursors (Bondy and Cheng, 2004; Popken et al., 
2004; Varela-Nieto et al., 2003). 
IGF-1 also has important roles in the hearing in mammals because defects in 
murine and human IGF-1 signaling cause severe impairments in sensorineural 
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hearing (Bonapace et al., 2003; Cediel et al., 2006; Walenkamp et al., 2005; 
Woods et al., 1996). 
IGF-1 binds to its receptor, IGF-1 tyrosine kinase receptor (IGF-1R), and 
activates two main pathways by phosphorylation (Varela-Nieto et al., 2003). 
The first pathway is the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in 
which phosphorylated PI3K activates Akt to achieve cell survival (Datta et al., 
1999) and cell cycle promotion (Medema et al., 2000; Zhou et al., 2001). The 
second pathway, the MEK/ERK pathway, is composed of Ras, Raf, and MEK, 
which activate the mitogen-activated protein kinases (MAPK) or extracellular 
signal-regulated kinases (ERK) 1/2, leading to an anti-apoptotic response 
(Finlay et al., 2000; Holmström et al., 1999) and cell proliferation (Pagès et al., 
1993). PI3K also activates the MEK/ERK pathway through protein kinase C 
(PKC) (Chung et al., 2006). 
The organ of Corti, which transduces sound signals to electrical signals in the 
cochlea, is composed of inner and outer hair cells (HCs) and supporting cells 
(SCs). After birth, the mammalian cochlear HCs cannot regenerate following 
injury because both HCs and SCs lose their ability to proliferate during 
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embryogenesis (Laine et al., 2010; Ruben, 1967). As cochlear HC damage is the 
cause of most sensorineural hearing loss (SNHL), a complete recovery from 
SNHL is difficult. Although glucocorticoid is an effective treatment for acute 
SNHL, this treatment improves hearing levels in only half of the patients 
treated (Hu and Parnes, 2009). 
We have considered IGF-1 as an alternate treatment to glucocorticoid due to its 
relevance to hearing function, its cell proliferation potential on vertebrate inner 
ear HCs (León et al., 1995; Oesterle et al., 1997; Zheng et al., 1997), and its 
anti-apoptotic actions. Our group previously reported that, in vivo, IGF-1 could 
protect cochlear HCs against noise exposure (Iwai et al., 2006; Lee et al., 2007) 
and ischemic injury (Fujiwara et al., 2008). Furthermore, our clinical trial 
showed the effectiveness of IGF-1 treatment in patients with idiopathic sudden 
sensorineural hearing loss that is refractory to glucocorticoid treatment 
(Nakagawa et al., 2010). 
However, the cellular mechanisms and downstream signals of IGF-1 action on 
damaged cochlear HCs still remain to be elucidated. To clarify these unknown 
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steps and factors, we took advantage of cochlear explant culture systems. In 
such systems, the activated downstream pathways can be easily detected using 
inhibitors that block various points of the IGF-1 signaling pathways; 
furthermore, such systems facilitate the observation of the death or promotion 




IGF-1 protects cochlear hair cells against neomycin 
In our previous studies, we found that IGF-1 protected hair cells from noise 
exposure (Iwai et al., 2006; Lee et al., 2007) and ischemic injury (Fujiwara et al., 
2008). However, these insults cannot be applied to the explant culture system. 
Therefore, we used aminoglycoside (neomycin), which is commonly used in this 
type of study (Kikkawa et al., 2009; Yoshida et al., 2011) to injure hair cells of 
cochlear explants. The administration of 100 ng/ml of IGF-1 markedly protected 
both the inner and outer hair cells (IHCs and OHCs) from neomycin injury 
(Figure 1A and B). This effect was statistically significant for both the OHCs 
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and IHCs (p<0.0001 for OHCs and p=0.0018 for IHCs, one-way ANOVA) 
(Figure 1C and D) and was dose-dependent (Figure 1C and D). 
 
Inhibition of the PI3K/Akt, MEK/ERK, or PKC pathways attenuates IGF-1 
cochlear hair cell protection 
To determine which downstream pathways were involved in the IGF-1 
protection of the hair cells, we administered an inhibitor of each pathway in 
addition to IGF-1, based on the requirement that an inhibitor whose target 
pathway is involved in the IGF-1 effect should attenuate the hair cell-protection 
effect. As a preliminary experiment, we added each inhibitor to the cochlear 
explants and confirmed that none was toxic to the hair cells at the 
concentrations used in this study (data not shown). 
The protection of the OHCs was significantly attenuated by PD98059 (ERK1 
inhibitor, p=0.0024, Figure 2A and F) and U0126 (ERK1/2 inhibitor,  p<0.0001 
Figure 2B and F), where p<0.0033 is considered statistically significant by 
Bonferroni corrction. In contrast, only U0126 significantly attenuated the 
protection effect on IHCs (p=0.0005 Figure 2 B and G). The U0126 treatment 
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had a tendency to have greater attenuation effects than PD98059 even in OHCs 
(Figure 2A, B, and F). These findings indicated that the MEK/ERK pathway 
was involved in the IGF-1 hair cell protection effect and that both ERK1 and 
ERK2 or only ERK1 might contribute to this effect in OHCs. ERK2 might be 
important in the protection of IHCs and ERK1 is only involved in the protection 
of OHCs. 
The treatment with LY294002, a PI3K inhibitor, significantly attenuated the 
IGF-1 protection of the OHCs and IHCs (OHC: p=0.0003 and IHC: p<0.0001, 
Figure 2C, F, and G), which indicated that PI3K is involved in IGF-1 protection 
in both OHCs and IHCs. 
Two molecules, Akt and PKC, were reported to be activated in the downstream 
pathways of PI3K signaling (Chung et al., 2006). To identify which downstream 
pathways were involved in the IGF-1 protective effects on the cochlear explant 
cultures, we administered an inhibitor of Akt (Akt inhibitor VIII) or PKC 
(calphostin C) to the damaged explants in addition to IGF-1. The treatment 
with Akt inhibitor VIII caused the attenuation of the hair cell protection in the 
IHCs only (OHC: p=0.0372 and IHC: p=0.0002, Figure 2D, F, and G). In 
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contrast, the treatment with calphostin C caused the attenuation of hair cell 
protection in both the OHCs and IHCs, as observed with the ERK1/2 and PI3K 
inhibitors (OHC: p<0.0001 and IHC: p=0.0002, Figure 2E, F, and G). These 
findings indicated that the activation of PI3K by IGF-1 in the cochlear explants 
involved both of these signaling molecules (Akt and PKC). However, these 
molecules have different roles. Akt contributed to the protection of IHCs only; in 
contrast, PKC contributed to the IGF-1 protection of both the OHCs and IHCs 
against neomycin in the cochlea. 
 
Activation of IGF-1 downstream signals occurred in the inner sulcus cells and 
the Hensen’s and Claudius’ cells 
To determine which cell populations in the cochlear sensory epithelium are 
acted upon by IGF-1, we investigated the expression of the IGF-1 receptor, 
IGF-1R, in the cochlea using immunohistochemistry. The IGF family which is 
related to insulin includes IGF-1 and IGF-2, and although both of these 
molecules can bind to IGF-1R (Baserga et al., 2003), IGF-1 has the highest 
binding affinity to IGF-1R (Brodt et al., 2000). 
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Immunohistochemistry using cryosection and whole mounts showed that 
IGF-1R was expressed in the membranes of the OHCs (Figure 3A and B), IHCs 
(Figure 3A and B), pillar cells (Figure 3A and B), inner sulcus cells (asterisks in 
Figure 3A and B), and Hensen’s and Claudius’ cells (double asterisks in Figure 
3A and B). The inner sulcus cells and the Hensen’s and Claudius’ cells are cell 
populations that are located medial to the IHCs and lateral to OHCs, 
respectively, in the cochlea. The pillar cells are located between the IHCs and 
OHCs. The pillar, Hensen’s and Claudius’ cells are considered SCs. Because our 
results suggest that IGF-1 may act on the OHCs, IHCs, and pillar, inner sulcus, 
and Hensen’s and Claudius’ cells, to specify which downstream signals of IGF-1 
are activated in the various cell populations, we investigated the expression 
patterns of the activated forms of Akt (phosphorylated Akt, p-Akt) and ERK 
(phosphorylated ERK, p-ERK) using immunohistochemistry. We chose the 
phosphorylated forms of these two molecules because IGF-1/IGF-1R signaling 
converges on Akt and ERK. In addition to Akt and ERK, PKC is also involved in 
the protection of hair cells. As shown previously, PKC eventually activates ERK 
(Chung et al., 2006), suggesting that p-ERK also reflects the activation of PKC. 
13 
 
Signal detection was performed 15 min following the administration of 
neomycin with or without IGF-1. 
When treated with neomycin only, we did not find any p-Akt or p-ERK signals 
in the cochlear epithelium (Figure 3C and E). As expected from our study using 
inhibitors, the addition of IGF-1 caused the activation of both Akt and ERK 15 
min after the IGF-1 administration (Figure 3D and F). We found variability in 
the localization of each signal. p-Akt was positive in the inner sulcus cells only 
(asterisk in figure 3D), whereas p-ERK was positive in the Hensen’s cells and 
Claudius’ cells (double asterisk in Figure 3F). The results of the p-Akt 
immunohistochemistry suggested that the inner sulcus cells with activated Akt 
can protect the adjacent IHCs from neomycin. This supports the results 
obtained from the inhibitor experiment (Figure 2D) and indicates that Akt is an 
important signal for the protection of IHCs. 
 
IGF-1 inhibits apoptosis in OHCs and IHCs  
The maintenance of the number of HCs, i.e. HC protection, can be achieved via 
two possible cellular mechanisms: the inhibition of cell death and the promotion 
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of cell proliferation. Previous reports examining other organs including nervous 
systems, bones, and mammary glands clarified that IGF-1 regulates both 
mechanisms (Varela-Nieto et al., 2007). Thus, to determine whether IGF-1 
inhibits the apoptosis of OHCs and IHCs that was induced by neomycin 
treatment, we evaluated the apoptosis status of the hair cells after the 
treatment with neomycin or with neomycin and IGF-1 by cleaved caspase-3 
immunohistochemistry. 
At 3 h following the administration of neomycin, the addition of IGF-1 did not 
cause a statistically significant decrease in the number of cleaved 
caspase-3-positive HCs (Figure 4A, B and E). However, the neomycin-treated 
group had a very low but some number of caspase-3-positive HCs (Figure 4A 
and E), which were not observed in the neomycin+IGF-1 group (Figure 4B and 
F). When we tested the status of apoptosis at 24 h following neomycin 
administration, we found significantly decreased number of 
caspase-3-positive-HCs (p<0.0001, Figure 4F) in the neomycin+IGF-1 group 
(Figure 4D) compared with the neomycin-only group (Figure 4C), and we found 
many cleaved caspase-3-positive HCs in both the OHCs and the IHCs in the 
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neomycin-only group. These results indicated that IGF-1 inhibited the 
neomycin-induced apoptosis of OHCs and IHCs. 
 
IGF-1 promotes the cell cycles in Hensen’s and Claudius’ cells 
Next, we considered another mechanism to explain the maintenance of the 
number of HCs, i.e., the promotion of HC or SC cell cycle. To test this hypothesis, 
we administered BrdU together with neomycin or with neomycin and IGF-1. 
BrdU is a synthetic nucleoside and an analog of thymidine that becomes 
incorporated into the nucleus during the S phase of mitosis. 
When treated with neomycin, BrdU-positive cells were observed in none of 
cochlear HCs and in very few SCs (Figure 5A), indicating that almost no S 
phase entry occurred in these cell populations. The addition of IGF-1 caused a 
significant uptake of BrdU in the Hensen’s and Claudius’ cells (Figure 5B and C, 
p=0.0042). These data indicated that IGF-1 induced the S-phase entry of the 
Hensen’s and Claudius’ cells after neomycin administration. To confirm the cell 
cycle promotion by IGF-1, we examined expression of phophohistone H3 (pHH3), 
an M phase marker of the cell cycle. Immunohistochemistry of pHH3 6 h after 
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the treatment with neomycin or with neomycin and IGF-1 showed that the 
addition of IGF-1 caused significant increase of the pHH3 positive cell number 
in the Hensen’s and Claudius’ cells (Figure 5D–F). Combined with the result of 
BrdU uptake, this result indicates that IGF-1 induced promotion of the cell 
cycle in the Hensen’s and Claudius’ cells. 
As the IGF-1 treatment caused the maintenance of the HC numbers, we 
hypothesized that the proliferation of the Hensen’s and Claudius’ cells, in 
addition to the inhibition of HC apoptosis, contributed to the maintenance of the 
HC numbers after the neomycin treatment. To test our hypothesis, we observed 
the IGF-1 protection of the HCs after inhibiting proliferation using aphidicolin 
or L-mimosine. Aphidicolin is a specific inhibitor of DNA polymerase  and  
and it blocks the cell cycle at early S phase (Hammond et al., 1987). L-Mimosine 
is a tyrosine analog that can arrest the cell cycle in the late G1 phase (Perry et 
al., 2005; Thompson et al., 1969). As a preliminary experiment, we determined 
that 2.8 M of aphidicolin or 0.1 mM of L-mimosine was a sufficient 
concentration to inhibit BrdU uptake in the Hensen’s and Claudius’ cells even 
when the explants were treated with IGF-1 (supplementary figure 3A and B). 
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We also confirmed that neither the aphidicolin or L-mimosine treatment nor the 
combination of IGF-1 and aphidicolin or L-mimosine treatment was toxic to the 
cochlear explant cultures (data not shown, supplementary figure 3E–G).  
The addition of aphidicolin or L-mimosine to the explants that were treated 
with neomycin and IGF-1 significantly attenuated the IGF-1 protection effect on 
the OHCs against neomycin (p=0.0274, Figure 6A and B for aphidicolin and 
p=0.0099, Figure 6C and D for L-mimosine). To exclude the possibility that the 
combination of neomycin, IGF-1, and aphidicolin induces the apoptosis of HCs, 
we examined the numbers of caspase-3-positive HCs in neomycin + IGF-1 group 
and neomycin + IGF-1 + aphidicolin group. We did not find difference in the 
numbers of caspase-3-positive HCs between these groups (data not shown). 
These results indicated that the cell cycle induction of the Hensen’s and 
Claudius’ cells with IGF-1 at least partly contributes to the maintenance of the 






In this study we found that the application of IGF-1 attenuates the loss of HCs 
that is induced by neomycin. Although the positive effects of IGF-1 against HC 
injury were evident from the previous studies showing that IGF-1 could protect 
the HCs from noise exposure and ischemic injury (Fujiwara et al., 2008; Iwai et 
al., 2006; Lee et al., 2007) and the present study, the activated downstream 
cascades of IGF-1 in the cochlea and the cellular mechanisms of HC protection 
by IGF-1 have remained unknown. We clarified the downstream cellular 
mechanisms using explant cultures of the neonate mouse cochlea. IGF-1 
controls cell proliferation, differentiation and apoptosis by binding to IGF-1R 
(Brodt et al., 2000). IGF-1R is a membrane receptor tyrosine kinase that 
transmits signals through several pathways, including the PI3K/Akt, 
MEK/ERK, and Janus kinases/signal transducers and activators of 
transcription (JAK/STAT) pathways (Brodt et al., 2000; Varela-Nieto et al., 
2007). 
Previous studies indicated that among these pathways, the PI3K/Akt and 
MEK/ERK pathways are involved in the protection of cochlear HCs within 
various contexts. The activity of the PI3K/Akt pathway diminishes after various 
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types of damage to HCs (Jiang et al., 2006; Selivanova et al., 2007) and the 
inhibition of the pathway worsens HC survival (Chung et al., 2006). The 
administration of dexamethasone, which is one of the most popular medications 
prescribed for the treatment of sensorineural hearing loss (Spear and Schwartz, 
2011), exerts its effects through the activation of the PI3K/Akt pathway (Haake 
et al., 2009). The MEK/ERK pathway is also involved in the protection of HCs 
from aminoglycoside toxicity (Battaglia et al., 2003). The downstream signaling 
cascades of IGF-1 include both of these pathways that are beneficial for HC 
protection. Whether all or only a portion of the downstream signaling cascades 
are activated by IGF-1 signaling is context-dependent. In embryonic inner ears, 
IGF-1 exerts its effects only through the PI3K/Akt pathway, resulting in the 
IGF-1-induced protection of neural progenitor cells in the otic vesicle (Aburto et 
al., 2012) and the regulation of the timing of sensory cell differentiation (Okano 
et al., 2011). Here we determined that IGF-1 activated both the PI3K/Akt and 
MEK/ERK pathways (Figure 3C-F) and protected the HCs from 
neomycin-induced damage when it was administered to the postnatal cochlear 
explants that had been damaged by neomycin (Figure 2). These results suggest 
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that the treatment with IGF-1 is a more efficient method to protect HCs than 
the activation of a single signal cascade. 
As demonstrated through anti-IGF-1R immunohistochemistry, IGF-1 can act on 
the OHCs, IHCs, inner sulcus cells, pillar cells and Hensen’s and Claudius’ cells 
(Figure 3A and B). However, using immunohistochemistry to identify 
phosphorylated IGF-1 downstream targets, we demonstrated that two 
downstream cascades of IGF-1 signaling were activated in the different cell 
populations (Figure 3C–F). p-Akt and p-ERK were detected in the inner sulcus 
cells (Figure 3D) and the Hensen’s and Claudius’ cells (Figure 3 H), respectively. 
The inhibition of Akt caused the attenuation of IHC protection but not OHC 
protection by IGF-1 (Figure 2D), supporting the result that the activation of Akt 
only occurred in the inner sulcus cells, which are located next to the IHCs. 
The possible cellular mechanisms for IGF-1 protection of the HCs are the 
mechanisms that are needed to maintain the HC numbers. To maintain the cell 
numbers, the inhibition of cell death and/or an increase in the number of cells 
are necessary, i.e., the inhibition of apoptosis and the proliferation of cells or cell 
cycle promotion are possible mechanisms by which IGF-1 exerts its effects in 
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the cochlea. In this study we determined that both of these mechanisms were 
involved in maintaining the numbers HCs (Figure 4 – 6).  
We were surprised by the detection of cell cycle promotion in the populations of 
Hensen’s and Caludius’ cells following the administration of IGF-1 to the 
neomycin-treated cochlear explants (Figure 5). We confirmed that this 
promotion of the cell cycle of the supporting cells contributed to the 
maintenance of the number of OHCs using an inhibitor of proliferation, 
aphidicolin (Figure 6A and B) and L-mimosine (Figure 6C and D). The 
administration of aphidicolin or L-mimosine reduced the number of OHCs but 
did not affect that of IHCs that were more distant from the Hensen’s and 
Caludius’ cells than the OHCs. This result suggested that the cell cycle 
promotion of the Hensen’s and Claudius’ cells contributed to the maintenance of 
the OHC numbers and that the proximity of these SCs to the OHCs caused this 
phenomenon to occur only in the OHCs. In birds, which can regenerate HCs, 
both the transdifferentiation of the SCs into HCs (Roberson et al., 2004; Shang 
et al., 2010) and the proliferation of the sensory epithelia (Corwin and Cotanche, 
1988; Ryals and Rubel, 1988) occur in the basilar papillae, the hearing organ of 
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the bird, following aminoglycoside-induced HC damage. The maintenance of the 
OHC numbers in the mouse cochlea caused by the cell cycle promotion of the 
SCs suggested that both of the cell cycle promotion of SCs and their 
transdifferentiation into HCs are involved in the protection of the OHCs by 
IGF-1 in the postnatal mammal. This finding is astonishing because the natural 
regeneration of HCs has never been reported in the postnatal mammal due to 
the cessation of HC proliferation during the embryonic stage (Ruben, 1967). 
Here, we showed that OHC regeneration could be induced by IGF-1 treatment 
in neonatal mice, as reported in the avian inner ear (Oesterle et al., 1997). 
Although previous studies have reported the proliferation of postnatal 
mammalian vestibular sensory epithelial cells with various growth factors 
(Oesterle and Hume, 1999), our study is the first to report the induction of cell 
cycle promotion in the postnatal mammalian cochlear sensory epithelia using 
exogenous factors following HC damage. Myosin7a, a hair cell marker, did not 
co-localized with BrdU-positive cells (Figure 5B); therefore, it is possible that 
the SCs underwent cell cycle promotion and that they themselves 
transdifferentiated into OHCs, or that the SCs with cell cycle promotion 
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induced the transdifferentiation of other non-proliferating SCs into OHCs. 
Considering that we did not find any BrdU-positive OHCs (Figure 5B), the 
latter possibility is more likely. The cell autonomous transdifferentiation of 
Hensen’s and Claudius’ cells was induced by the inhibition of Notch signaling in 
the postnatal mouse cochlea (Yamamoto et al., 2006). Thus, a combination of 
IGF-1 treatment and inhibition of Notch signaling may achieve a more robust 
maintenance of the number of OHCs. 
We also found that the maintenance of the IHC and OHC numbers was 
regulated by different cellular mechanisms. As already discussed, the cell cycle 
promotion only contributed to the maintenance of the OHC numbers because 
the inhibition of mitosis affected only the OHC numbers (Figure 6B and D). In 
contrast, the cleaved caspase-3 staining clearly indicated that the inhibition of 
apoptosis contributed to the maintenance of the numbers of both OHCs and 
IHCs.  
As discussed above, the PI3K/Akt pathway was only involved in the 
maintenance of IHC numbers. The PI3K/Akt pathway appeared to exert its 
effects through the inhibition of apoptosis, even though its action was mediated 
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by the inner sulcus cells that were located medial to the IHCs, and no cell cycle 
promotion was observed around the IHCs (Figure 4C and 5B and E). Inner 
sulcus cells might provide some surviving factors to adjacent IHCs. In contrast, 
the MEK/ERK pathway was likely to be involved in the cell cycle promotion of 
the Hensen’s and Claudius’ cells for two reasons: p-ERK was detected in the 
Hensen’s and Claudius’ cells (Figure 3F) in which BrdU uptake and pHH3 were 
also detected, and the activation of MEK/ERK pathway causes the proliferation 
of SCs in the chicken basilar papillae, resulting in the regeneration of HCs (Bell 
and Oberholtzer, 2010). 
In summary, we found that IGF-1 could activate both the PI3K/Akt and 
MEK/ERK pathways in the neomycin-injured postnatal mouse cochlea. The 
PI3K/Akt pathway maintained the number of IHCs through the inhibition of 
apoptosis. The MEK/ERK pathway was activated in the Hensen’s and Claudius’ 
cells and induced the cell cycle promotion in these cells that partly contributed 
to the maintenance of the OHCs. Our findings showed that IGF-1 can be used as 
an efficient medication against the sensorineural hearing loss caused by 
cochlear HC damage.  
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Materials and Methods 
 
Animals 
ICR mice were purchased from Japan SLC, Hamamatsu, Japan. All of the 
experimental procedures were performed in accordance with the NIH Guide for 
the Care and Use of Laboratory Animals. The Animal Research Committee of 
the Graduate School of Medicine, Kyoto University, approved all of the 
experimental protocols. Animal care was given under the supervision of the 




The P2 mice cochleae were fixed in 4% paraformaldehyde in 0.1 M phosphate 
buffer at 4°C for 4 h, embedded in OCT compound (Tissue Tek, Miles Inc., IN, 
USA), and 10 m mid-modiolar sections were then prepared. For whole-mount 
immunohistochemistry, the samples were fixed at room temperature (RT) for 15 
min in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). 
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The specimens were rinsed with phosphate-buffered saline (PBS) and then 
incubated in blocking solution at room temperature (30 min in 10% goat serum 
with 0.2% TritonX-100 for Myosin7a, IGF-1R, phospho-ERK1/2, and BrdU; and 
15 min in 0.2% Triton X-100 and 15 min in 1% BSA in 0.2% Triton X-100 for 
phospho-Akt, cleaved caspase-3, and pHH3). 
The primary antibodies used in this study were rabbit polyclonal anti-Myosin7a 
(1:1000; Proteus Bioscience Inc., Ramona, CA, USA), rabbit polyclonal 
anti-IGF-1R (1:100; Cell Signaling Technology, Danvers, MA, USA), rabbit 
monoclonal anti-p-Akt (Ser473) (1:50; Cell Signaling Technology), mouse 
monoclonal anti-p-ERK1/2 (1:1000; Sigma-Aldrich), rabbit polyclonal 
anti-cleaved caspase-3 (1:100; Cell Signaling Technology), mouse monoclonal 
anti-BrdU (1:50; BD Biosciences), and p-HH3 mouse monoclonal (1:100; Cell 
Signaling, #9706). The actin filaments were visualized with Alexa-546- or 
-633-labeled phalloidin (1:100; Invitrogen, Grand Island, NY, USA).  The 
specificity of the anti-p-Akt and anti-p-ERK1/2 antibodies was confirmed using 
specific blocking peptides (p-Akt blocking peptide #1140 and p-ERK blocking 
peptide #1150 from Cell Signaling, Supplementary figure 1). 
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The primary antibodies were visualized with Alexa-488- or -546-conjugated 
anti-rabbit or anti-mouse goat IgG (1:1000; Invitrogen). The specimens for 
which nuclear staining was necessary were then incubated in PBS containing 2 
mg/ml DAPI (4′6-diamidino-2-phenylindole•2HCl) (Invitrogen).  
The omission of the primary antibodies was served as a negative control of 
immunohistochemistry. 
The fluorescent images were captured using a Leica TCS-SPE confocal 
microscope (Leica Microsystems Inc., Wetzlar, Germany).  
 
Preparation and treatment of cochlear sensory epithelium explant cultures 
The explant cultures were established as previously described (Yamamoto et al., 
2006). Briefly, postnatal day (P) 2 ICR mice were deeply anesthetized with 
carbon dioxide and then decapitated. The cochleae were dissected out of the 
heads with watchmaker forceps using a stereomicroscope. The organs of Corti 
were separated from the surrounding tissues and were placed onto cell culture 
inserts (Becton Dickinson, Franklin Lakes, NJ, USA). The cultures were 
incubated within Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich 
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Inc., St. Louis, MO, USA), supplemented with D-glucose (6 g/l) and penicillin G, 
at 37°C in a humidified 5% CO2 atmosphere. To exclude the possibility of effects 
caused by any growth factors or hormones contained in the serum, we used 
serum-free medium in all of the experiments. All of the experiments began 
following 24 h of incubation in the medium to stabilize the explants. 
To determine the effects of IGF-1 against aminoglycoside treatment on the 
cochlear explant cultures, the explants were maintained for 24 more hours (n = 
3–6) in medium containing neomycin sulfate (Sigma-Aldrich, St. Louis, MO, 
USA) at a concentration of 2 mM with or without recombinant human IGF-1 at 
the specified concentration (Astellas Pharma Inc., Tokyo, Japan). 
To determine the downstream effects of IGF-1 on the damaged cochlear HCs, 
various inhibitors of IGF-1 downstream signaling were added to the explant 
cultures. The explants were treated for 24 h with medium containing 2 mM 
neomycin, 100 ng/ml IGF-1, and various inhibitors, LY294002 (10 M, PI3K 
inhibitor, Merck Chemicals, Darmstadt, Germany), Akt inhibitor VIII (10 M, 
Akt inhibitor, Merck Chemicals), PD98059 (10 M, ERK1 inhibitor, Merck 
Chemicals), U0126 (10 M, ERK1/2 inhibitor, Merck Chemicals), and calphostin 
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C (100 nM, PKC inhibitor, Sigma-Aldrich) (n = 4–6). Specificity of each inhibitor 
was confirmed by immunohistochemistry of the specific target (Supplementary 
figure 2). 
To specify the location of Akt or ERK activation within the cochlear epithelium, 
the explants were stained with anti-phospho-Akt or anti-phospho-ERK 
antibodies after incubation with 2 mM neomycin or both 100 ng/ml IGF-1 and 2 
mM neomycin for 15 min (n = 3–5). We chose this time point because previous 
study showed that activation of phospho-Akt and phospho-ERK by IGF-1 
occurred between 10 and 30 min after IGF-1 administration (Mairet-Coello et 
al., 2009). 
The apoptotic status of the cochlear epithelium was estimated by 
immunostaining the explants with anti-cleaved caspase 3 antibodies after 3 or 
24 h incubations with 2 mM neomycin or both 100 ng/ml IGF-1 and 2 mM 
neomycin (n = 5–7). 
The promotion of the cell cycle by IGF-1 in the cochlear explants was visualized 
using BrdU and immunohistochemistry of phophohistone H3 (pHH3). BrdU (3 
g/ml, BD Biosciences, Franklin Lakes, NJ) was added to the explant cultures 
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during a 24 h treatment with 2 mM neomycin or both 100 ng/ml IGF-1 and 2 
mM neomycin and the explants were double-immunostained with anti-BrdU 
and anti-Myosin7a antibodies (n = 3 or 4). Immunohistochemistry of pHH3 was 
performed 6 h after treatment with 2 mM neomycin or both 100 ng/ml IGF-1 
and 2 mM neomycin. To confirm that the cell cycle promotion of the supporting 
cells contribute to the maintenance of the number of hair cells, explants were 
treated with 2 mM neomycin and 2.8 mM aphidicolin (Sigma-Aldrich) or 0.1mM 
L-mimosine (Calbiochem) ± 100 ng/ml IGF-1 for 24 h (n = 4–6). The specificity 





The numbers of inner and outer HCs or SCs in the organ of Corti were counted 
along a 100 m-longitudinal distance in the basal turn of each explant except 
pHH3-positive cells. For pHH3-positive cells, the number of pHH3-positive SCs 
in one high power field (275 µm × 275 µm) was counted. We analyzed the 
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basal turn of the cochlea in this study because hair cells in the apex are 
resistant to aminoglycosides. The hair cells with remaining stereocilia were 
counted as live hair cells, and the stereocilia were identified using phalloidin to 
detect the actin filaments. The cleaved caspase-3-positive cells were defined as 
those that had hair bundles stained with phalloidin, and only the BrdU or 
pHH3-positive cells that were co-stained with DAPI and that existed in the 
epithelial layer were counted. 
 
Statistical analysis 
The data were expressed as the mean ± standard errors. One-way ANOVA was 
used for the analysis of the protection effects of IGF-1 against neomycin. Post 
hoc tests were performed by the Bonferroni method. In the other experiments, 
the statistical analyses were performed using unpaired t-tests, and Bonferroni 
correction was applied on the multiple comparisons of the effects of various 
inhibitors of IGF-1 signaling. p values below 0.05 were considered statistically 
significant except in the cases analyzed with Bonferroni correction. p values 
below 0.0024 or 0.0033 was considered statistically significant in the analysis of 
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dose dependency of IGF-1 effects or various inhibitors of IGF-1 signaling, 
respectively. 
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Figure Legends 
Figure 1. IGF-1 protected cochlear hair cells against neomycin damage. 
A and B. Representative images of cochlear explants immunostained with 
anti-myosin 7a (myo7a, green) and phalloidin (red) after the treatment with 
neomycin only (A) or neomycin and 100 ng/ml of IGF-1 (B). C and D. The 
number of surviving hair cells after neomycin and various concentrations of 
IGF-1 treatment were counted. Both the inner and outer hair cells (IHCs and 
OHCs) were destroyed by the presence of neomycin (A). The addition of 100 
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ng/ml IGF-1 dramatically improved the survival of the IHCs and OHCs (B). 
IGF-1 significantly attenuated the loss of the OHCs (C, p<0.0001) and IHCs (D, 
p=0.0018) in neomycin-damaged cochlear sensory epithelia. Lower 
concentrations of IGF-1 were less able to protect the cochlear hair cells. 
The scale bar represents 25 m. The bars represent the standard errors. 
*p<0.001; **p=0.0011; ***p<0.003 by Bonferroni method. 
 
Figure 2. Blockage of PI3K/Akt, MEK/ERK or PKC attenuated the protective 
effect of IGF-1 on neomycin-induced cochlear hair cell damage. 
A–E. PD98059 (A, 10 M), U0126 (B, 10 M), LY294002 (C, 10 M), Akt 
inhibitor VIII (D, 10 M) or calphostin C (E, 100 nM) were administered to the 
cochlear explants in addition to 2 mM neomycin and 100 ng/ml IGF-1 for 24 h. 
The specimens were immunostained with anti-myosin 7a (myo7a, green) and 
phalloidin (red), and the number of cochlear hair cells with remaining 
stereocilia was counted. F and G. The number of surviving OHCs (F) and IHCs 
(G) after neomycin treatment with various inhibitors of the IGF-1 downstream 
pathways was counted. When treated with U0126 (B), LY294002 (C), or 
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calphostin C (E), the protection of both the OHCs and IHCs was significantly 
attenuated (F and G). In contrast, when treated with PD98059 (A) or Akt 
inhibitor VIII (C), only the OHC or IHC protection was significantly attenuated, 
respectively (F and G). These findings indicated that the MEK/ERK or 
PI3K/PKC pathway and the PI3K/Akt pathway were involved in the protection 
of the HCs in different ways. Although off-target effects should be considered, 
these results suggest that the PI3K/Akt pathway protects only IHCs and the 
other pathways protect both the IHCs and OHCs. The scale bar in E represents 
25 m. The bars in F and G represent the standard errors. *p=0.0024; 
**p<0.0005; ***p<0.001 by Bonferroni correction. 
 
Figure 3. Identification of cochlear cell populations that are protected by 
IGF-1. 
A and B. Immunohistochemistry of IGF-1R (green) on a cross section (A) or 
whole mount (B) of postnatal day 2 (P2) mouse cochlea. C–F. 
Immunohistochemistry of phospho-Akt (green, C and D) and phospho-ERK 
(green, E and F) in the mouse cochlear explants grown in the neomycin 
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containing media with (D and F) or without (C and E) IGF-1. G and H. Primary 
antibody omission experiment for phospho-Akt (G) and phospho-ERK (H) grown 
in the neomycin containing media with IGF-1. The specimens were 
counterstained with phalloidin (red in A–D and purple in E and F) and DAPI 
(blue). IGF-1R was expressed in the OHCs, IHCs, inner sulcus cells (asterisks in 
A and B), pillar cells, and Hensen’s and Claudius’ cells (double asterisks in A 
and B). When the explants were treated with neomycin (Neo) only, neither 
phospho-Akt nor phospho-ERK positive cells were detected in the cochlear 
sensory epithelia. When the explants were treated with neomycin and IGF-1, 
the phospho-Akt and phospho-ERK were detected in the inner sulcus cells 
(asterisk in D) and in the Hensen’s and Claudius’ cells (double asterisk in F), 
respectively. * and ** indicate the area of the inner sulcus cells and the Hensen’s 
and Claudius’ cells, respectively. The scale bar in A represents 50 m. The scale 
bars in B, C, E, G, and H represent 25 m. 
 
Figure 4. IGF-1 protected cochlear hair cells from apoptosis. 
A–D. The explants were cultured for 3 (A and B) or 24 (C and B) hours in 
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neomycin (Neo) containing media with (B and D) or without (A and C) the 
addition of IGF-1. The specimens were immunostained with anti-cleaved 
caspase-3 antibody (green) and phalloidin (red), and the numbers of apoptotic 
cochlear hair cells were counted in the 3 (E) or 24 (F) h conditions. We detected 
very few cleaved caspase-3-positive hair cells in the Neo+IGF-1 samples (B and 
D), although we did detect cleaved caspase-3-positive cells in the neomycin-only 
samples (A and C). The difference in the number of cleaved caspase-3-positive 
hair cells was significant only in the 24 hour treatment experiments (E and F). 
The scale bar represents 25 m. The bars represent standard errors. *p<0.0001 
by Student’s t-test. 
 
Figure 5. IGF-1 induced cell cycle promotion in Hensen’s and Claudius’ cells. 
A and B. BrdU incorporation was tested by immunohistochemistry in the 
cochlear explants treated with neomycin (Neo) (A) or with both Neo and IGF-1 
(B) for 24 h. The specimens were immunostained with anti-BrdU antibody 
(green), anti-myosin7a antibody (myo7a, red) and DAPI (blue). C. The number 
of BrdU-positive cells was counted. D and E. Phospho-histone H3 (pHH3, green) 
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and myosin7a (myo7a, red) were immunostained in the cochlear explants 
treated with neomycin (Neo) (D) or with both Neo and IGF-1 (E) for 6 h. DAPI 
was used as counterstain of the specimens. F. The number of pHH3-positive 
cells was counted. The samples that were treated with neomycin contained only 
a small number of BrdU- or pHH3-positive cells (A, C, D, and F). The addition of 
IGF-1 resulted in a significantly increased number of BrdU- (B and C, 
p=0.0042) or pHH3- (E and F, p=0.0159) positive cells in the Hensen’s and 
Claudius’ cell region. The scale bars in B and E represents 25 m. The bars 
represent standard errors. hpf = high power field (275 µm ×  275 µm). 
*p=0.0042; **p=0.0159; by Student’s t-test. 
 
Figure 6. Inhibition of the cell cycle promotion attenuated the protective effect 
of IGF-1 on neomycin-induced cochlear hair cell damage. 
A and C. Representative images of a cochlear explant culture treated with 
neomycin (Neo), IGF-1, and an inhibitor of proliferation, aphidicolin (A) or 
L-mimosine (C). The specimens were immunostained with anti-myosin7a 
(myo7a, green) and phalloidin (red). B and D. The numbers of surviving OHCs 
42 
 
and IHCs after the neomycin and IGF-1 treatment with or without aphidicolin 
(B) or L-mimosine (D) were counted. The addition of aphidicolin or L-mimosine 
caused a significant attenuation of the IGF-1 OHC protection effect (B, 
p=0.0274, or D, p=0.0099). The scale bars in A and C represents 25 m. The bars 
represent standard errors. *p=0.0274; **p=0.0099; by Student’s t-test. 
Supplementary figure 1. Specificity of anti-phospho-Akt and 
anti-phospho-ERK antibodies was confirmed using specific blocking 
peptides. 
After having been treated with 2 mM neomycin and 100 ng/ml IGF-1 for 15 
min the cochlear explants were immunostained with anti-phospho-Akt 
(green in A) and anti-phospho-ERK (green in B) antibodies that were 
incubated with specific blocking peptides in advance. The specimens were 
counterstained with phalloidin (red in A and purple in B). The signals of 
phospho-Akt and phospho-ERK observed in inner sulcus cells and Hensen’s 
and Claudius’ cells, respectively (Figure 3 D and F), were not detected 
(asterisk in A and double asterisk in B). These findings indicated the 
specificity of these primary antibodies. * and ** indicate the area of the inner 
sulcus cells and the Hensen’s and Claudius’ cells, respectively. The scale bars 
represent 25 m. 
 
Supplementary figure 2. Specificity of PI3K/Akt and MEK/ERK inhibitors 
The cochlear explants were treated with LY294002 (A and E, 10 M), Akt 
inhibitor VIII (B and F, 10 M), PD98059 (C and G, 10 M) or U0126 (D and 
H, 10 M) in addition to 2 mM neomycin and 100 ng/ml IGF-1 for 15 min. 
The specimens were immunostained with anti-phospho-Akt (green in A–D) 
or ERK (green in E–H) antibody and were counterstained with phalloidin 
(red in A–D and purple in E–H). Phospho-AKT signal were inhibited by PI3K 
(A) and AKT (B) inhibitors but not by MEK inhibitors (C and D). In contrast, 
phospho-ERK signals were inhibited by PI3K (E) and MEK (G and H) 
inhibitors but not by AKT inhibitors (F). Considering that PI3K can affect 
MEK/ERK signaling through PKC, these results clearly showed that each 
inhibitor specifically block its target. AKT inhibitor VIII can decrease the 
production of phospho-AKT by inhibiting AKT kinase. * and ** indicate the 
area of the inner sulcus cells and the Hensen’s and Claudius’ cells, 
respectively. The scale bars in A and E represent 25 m. 
 
Supplementary figure 3. Specificity and toxicity of aphidicolin and 
L-mimosine. 
A and B. BrdU incorporation was tested by immunohistochemistry in the 
cochlear explants treated with 2 mM neomycin, 100 ng/ml IGF-1 and 2.8 mM 
aphidicolin or 0.1 mM L-mimosine for 24 h. The specimens were 
immunostained with anti-BrdU antibody (green), anti-myosin7a antibody 
(myo7a, red) and DAPI (blue). C and D. The number of BrdU-positive cells 
was counted. Aphidicolin or L-mimosine treatment significantly decreased 
the number of BrdU positive Hensen’s and Claudius’ cells (*p=0.0009 in C 
and **p=0.0083 in D by Student’s t-test). E–G. The cochlear explants were 
treated with 2.8 mM aphidicolin and 100 ng/ml IGF-1 (F) or 0.1 mM 
L-mimosine and 100 ng/ml IGF-1 (G) for 24 h. The non-treated specimen was 
presented as a control sample (E). The specimens were immunostained with 
anti-myosin 7a antibody (myo7a, green) and were counterstained with 
phalloidin (red). H and I. The number of cochlear outer and inner hair cells 
(OHC and IHC) with remaining stereocilia was counted. The numbers of 
OHC and IHC in the samples treated with aphidicolin or L-mimosine were 
not reduced in comparison with those of the control samples (H: p=0.0933 in 
OHC and p=0.6504 in IHC; I: p=0.2354 in OHC and p=0.7791 in IHC by 
Student’s t-test). These findings indicated that aphidicolin or L-mimosine in 
this concentration with IGF-1 is not toxic to the hair cells in the cochlear 
explants. The scale bars in B and G represent 25 m. The bars represent 
standard errors.  









